Skip to content
Bored Studies
RecruitingPhase 3

An Efficacy and Safety Study of DFL24498 in the Treatment of AKC

Dompé Farmaceutici S.p.A · NCT07395232

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 10–65 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
153
US sites recruiting
8
Study start
December 1, 2025
Record last updated
September 21, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This is a phase 3, multicenter, randomized, double-masked, parallel-group, vehicle-controlled study to evaluate the safety and efficacy of DFL24498 compared with vehicle ophthalmic solution, in participants with AKC. The study consists of 2 cohorts: the adult cohort includes approximately 138 participants and the pediatric cohort which includes approximately 15 participants. The cohorts will be randomized separately. Adult participants will be randomized in a 1:1 ratio, while pediatric participants will be randomized in a 2:1 ratio to receive DFL24498 or vehicle.

Being studied: DFL24498; Vehicle; dexamethasone sodium phosphate (DSP) ophthalmic solution

Conditions: Atopic Keratoconjunctivitis

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

  • Male or Female aged ≥ 10 and ≤ 65 years.
  • Diagnosis of AKC in both eyes, including the presence or medical history of the following:
  • other atopic condition (ie., atopic dermatitis, periocular eczema, asthma, allergic rhinitis), AND
  • chronic allergic blepharoconjunctivitis and/or keratoconjunctivitis.
  • Ocular itching of at least 50 as assessed by VAS scale.
  • Corneal fluorescein staining assessed by modified Oxford scale of at least grade 1 AND a bulbar conjunctival hyperemia assessed by VBR 10 scale of at least 40 (range 0 to 100) in the same eye.
  • A composite symptoms score (CSyS) ≥ 5 (sum of the severity scores graded 0 to 3 for each of the following: itching, tearing, ocular discomfort, photophobia, and mucous discharge score) (CSyS range of 0 to 15).
  • If a woman of childbearing potential (WOCBP), must have a negative pregnancy test at both screening and baseline visit, and use an acceptable contraception method.

Exclusion Criteria

Participants will be excluded if any of the following criteria apply:

  • Inability to speak and understand the local language sufficiently to understand the nature of the study, to provide written informed consent, and to allow the completion of all study assessments.
  • Evidence of an active ocular infection in either eye.
  • Intraocular inflammation defined as anterior chamber flare > 0 by Standardization of Uveitis Nomenclature (SUN) grading, in either eye.
  • Known or suspected ocular malignancy (ocular surface, intraocular, ocular adnexa).
  • Presence of cancer or any other systemic or unstable disease that may affect the ability to participate in the clinical study in the opinion of the investigator including basal cell carcinoma.
  • Participants that are anatomically monocular.
  • Systemic disease not stabilized within 1 month before the screening visit (eg, diabetes with glycemia out of range, thyroid malfunction) or judged by the investigator to be incompatible with the study (eg, current systemic infections) or with a condition incompatible with the frequent assessment required by the study.

Note: Additional protocol defined Inclusion/Exclusion criteria apply

Recruiting US locations

  • Bowden Eye Associates - Southside Location

    Jacksonville, FL 32256

  • University of Miami, Miller School of Medicine, Bascom Palmer Eye Institute

    Miami, FL 33136

  • Clayton Eye Clinical Research

    Morrow, GA 30260

  • Ophthalmology Associates

    St Louis, MO 63131

  • NYU Langone Health - Eye Center

    New York, NY 10017

  • Duke Eye Center - Ophthalmology

    Durham, NC 27710

  • Total Eye Care, PA

    Memphis, TN 38119

  • Baylor University Jamail Specialty Care Center- Alkek Eye Center- Ophthalmology

    Houston, TX 77030

Study contacts (from the official record)

  • Dompé farmaceutici S.p.A. Via Santa Lucia, 6, 20122 Milan (MI) · +39 02 583 831
An Efficacy and Safety Study of DFL24498 in the Treatment of AKC (NCT07395232) | Bored Studies